Therapeutic Drug Monitoring and Dose Optimization of Pegaspargase in AYA ALL

Dr. Silverman opens a discussion on dose capping and empiric dose reduction of pegaspargase (PEGylated asparaginase) in the adult and AYA setting. Dr. Curran notes that cooperative group trials in AYA ALL now standardly dose cap pegaspargase at 3,750 IU (one vial) rather than weight-based dosing. Beyond dose capping, some adult programs empirically reduce the starting dose to 1,000 IU/m2 rather than the standard 2,000 IU/m2, following levels by therapeutic drug monitoring (TDM) to confirm that therapeutic asparaginase enzyme activity is still achieved. Data from Dr. Curran's former institution and European groups suggest that most patients achieve therapeutic activity levels even at reduced doses of 1,000 IU/m2, and some at 500 or 250 IU/m2.

Dr. Silverman notes from extensive experience running pediatric ALL trials that at doses of 2,500 IU/m2, the vast majority of patients are well above the therapeutic threshold throughout the dosing interval. He describes asparaginase as likely operating via an all-or-none mechanism: if the enzyme activity is maintained above the therapeutic target, asparagine depletion is achieved regardless of whether the dose is at standard or reduced levels. He confirms that dose capping is unlikely to compromise therapeutic efficacy.

Therapeutic drug monitoring targets an asparaginase enzyme activity level of at least 0.1 IU/mL at nadir, based on historical data linking this threshold to asparagine depletion. Dr. Silverman contextualizes the evidence: this level was established using technically demanding serum asparagine measurement studies where samples had to be handled under highly controlled conditions to prevent in-vitro asparagine breakdown. The 0.1 IU/mL threshold is accepted but may not be precisely defined at the individual patient level.

Both panelists check enzyme activity levels at 7 and 14 days after a pegaspargase dose, and Dr. Silverman also at 21 days for calaspargase pegol (longer half-life). Dr. Curran adds that in patients with prior hypersensitivity or suspected silent inactivation, checking the level immediately at the end of infusion can provide early confirmation of whether drug is active.